Ratio of free or complexed prostate-specific antigen (PSA) to total PSA: Which ratio improves differentiation between benign prostatic hyperplasia and prostate cancer?

Clinical Chemistry

Volumn 46, Issue 1, 2000, Pages 55-62

  Jung, Klaus ^a   Elgeti, Ulrike ^a   Lein, Michael ^a   Brux, Brigitte ^a   Sinha, Pranav ^a   Rudolph, Birgit ^a   Hauptmann, Steffen ^a   Schnorr, Dietmar ^a   Loening, Stefan A ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

PLASMA PROTEIN; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; ASSAY; CONTROLLED STUDY; HUMAN; MAJOR CLINICAL STUDY; MALE; PROSTATE CANCER; PROSTATE HYPERTROPHY;

EID: 0033974760     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinchem/46.1.55     Document Type: Article

References (32)

1. 1. Catalona WJ. Measurement of prostate-specific antigen in serum as screening test for prostate cancer. New Engl J Med 1991;324: 1156-61.
2. 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. Cancer Res 1991;51: 222-6.
3. 1-antichymotrypsin. Clin Chem 1991;37:1618-25.
4. 1-antichymotrypsin as an indicator of prostate cancer. J Urol 1993;150:100-5.
5. 5. Polascik TJ, Oesterling JE, Partin AW. Prostate specific antigen: a decade of discovery - what we have learned and where we are going. J Urol 1999;162:293-306.
6. 1-antichymotrypsin. Clin Chem 1993;39:2098-103.
7. 7. Wu JT, Zhang P, Liu GH, Wilson L. Development of an immunoassay specific for the PSA-ACT complex without the problem of high background. J Clin Lab Anal 1998;12:14-9.
8. 1-antichymotrypsin complex. Clin Chem 1995; 41:1480-8.
9. 9. Björk T, Piironen T, Pettersson K, Lövgren T, Stenman U-H, Oesterling JE, et al. Comparison of analysis of the different prostate-specific antigen forms in serum for detection of clinically localized prostate cancer. Urology 1996;48:882-8.
10. 10. Allard WJ, Zhou Z, Yeung KK. Novel immunoassay for the measurement of complexed prostate-specific antigen in serum. Clin Chem 1998;44:1216-23.
11. 11. Meyer A, Jung K, Lein M, Schnorr D, Loening SA. Factors influencing the ratio of free to total prostate specific antigen in serum. Int J Cancer 1997;74:630-6.
12. 12. Passing H, Bablok W. A new biometrical procedure for testing the equality of measurements from two different analytical methods. Application of linear regression procedures for method comparison studies in clinical chemistry. Part I. J Clin Chem Clin Biochem 1983;21:709-20.
13. 13. Zhou Z, Armstrong EG, Belenky A, Freeman JV, Yeung KK. Equivalent recognition of free and ACT-complexed PSA in a monoclonal-polyclonal sandwich assay is conferred by binding specificity of the monoclonal antibody. J Clin Lab Anal 1998;12:242-9.
14. 14. Stamey TA, Chen Z, Prestigiacomo AF. Reference material for PSA: the IFCC standardization study. Clin Biochem 1998;31:475-81.
15. 15. Gion M, Mione R, Barioli P, Barichello M, Zattoni F, Prayer GT, et al. Percent free prostate-specific antigen in assessing the probability of prostate cancer under optimal analytical conditions. Clin Chem 1998;44:2462-70.
16. 1-antichymotrypsin complex for the screening and management of prostate cancer. J Clin Lab Anal 1998;12: 32-40.
17. 17. Espana F, Royo M, Martinez M, Enguidanos MJ, Vera CD, Estelles A, et al. Free and complexed prostate specific antigen in the differentiation of benign prostatic hyperplasia and prostate cancer: studies in serum and plasma samples. J Urol 1998;160: 2081-8.
18. 1-antichymotrypsin-prostate-specific antigen in patients with prostate carcinoma but not in those with benign prostate hyperplasia. Clin Chem 1999;45: 422-5.
19. 19. Brawer MK, Meyer GE, Letran JL, Bankson ER, Morris DL, Yeung KK, Allard WJ. Measurement of complexed PSA improves specificity for early detection of prostate cancer. Urology 1998;52: 372-8.
20. 20. Yemoto CE, Stamey TA. Observations on complexed serum PSA (cPSA) in separating biopsy-negative from biopsy-positive men in a university setting [Abstract]. J Urol 1999;161(Suppl):208.
21. 21. Gaspar MJ, Angulo J, Arribas I, Coca MC. Clinical utility of total, free and complexed PSA in the diagnosis of prostate carcinoma and benign prostate hyperplasia [Abstract]. Clin Chem 1999; 45(Suppl S6):A106.
22. 22. Rittenhouse HG, Chan DW. Can complexed PSA be used as a single test for detecting prostate cancer? [Editorial]. Urology 1999;54:4-5.
23. 23. Trinkler FB, Schmid DM, Hauri D, Pei P, Maly FE, Sulser T. Free/total prostate-specific antigen ratio can prevent unnecessary prostate biopsies. Urology 1998;52:479-86.
24. 24. Luderer AA, Chen YT, SorianoTF, Kramp WJ, Carlson G, Cuny C, et al. Measurement of the proportion of free to total prostate-specific antigen improves diagnostic performance of prostate-specific antigen in the diagnostic gray zone of total prostate-specific antigen. Urology 1995;46:187-94.
25. 25. Prestigiacomo AF, Lilja H, Pettersson K, Wolfert RL, Stamey TA. A comparison of the free fraction of serum prostate specific antigen in men with benign and cancerous prostates: the best case of scenario. J Urol 1996;156:350-4.
26. 26. Partin AW, Catalona WJ, Southwick PC, Subong ENP, Gasior GH, Chan DW. Analysis of percent free prostate-specific antigen (PSA) for prostate cancer detection: influence of total PSA, prostate volume, and age. Urology 1996;48(Suppl 6A):55-61.
27. 27. Van Cangh PJ, De Nayer P, De Vischer L, Sauvage P, Tombal B, Lorge F, et al. Free to total prostate-specific antigen (PSA) ratio improves the discrimination between prostate cancer and benign prostatic hyperplasia (BPH) in the diagnostic gray zone of 1.8 to 10 ng/mL total PSA. Urology 1996;48:67-70.
28. 28. Catalona WJ, Smith DS, Ornstein DK. Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurements. JAMA 1997;277:1452-5.
29. 29. Junker R, Brandt, Zechel C, Assmann G. Comparison of prostate-specific antigen (PSA) measured by four combinations of free PSA and total PSA assays. Clin Chem 1997;43:1588-94.
30. 30. Virtanen A, Gomari M, Kranse R, Stenman U-H. Estimation of prostate cancer probability by logistic regression: free and total prostate-specific antigen, digital rectal examination, and heredity are significant variables. Clin Chem 1999;45:987-94.
31. 31. Veltri RW, Miller MC, Zhao G, Vessella RL, Wright GLJ, Ng A. Evaluation of various molecular forms of PSA to distinguish benign prostatic hyperplasia (BPH) form prostate cancer (CaP) [Abstract]. J Urol 1999;161(Suppl):96.
32. 32. Demura T, Shinohara N, Harabayashi T, Hioka T, Takakura F, Togashi M, et al. Ratio of free and complexed PSA: the most powerful tool for detecting prostate cancer (CaP) [Abstract]. J Urol 1999;161(Suppl):317.